ERAS Erasca, Inc.
Erasca, Inc. (ERAS) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.2% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Erasca, Inc.
Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.